Epidermolysis bullosa pruriginosa with extensive truncal involvement treated with upadacitinib

Affiliations

¹ Department of Dermatology, College of Medicine, Hanyang University, Seoul, South Korea.
² Sung Kyung Jeh Skin Clinic, Seoul, South Korea.
³ Department of Pathology, College of Medicine, Hanyang University, Seoul, South Korea.

Nayoung Kim et al. J Eur Acad Dermatol Venereol. 2023 Feb.

. 2023 Feb;37(2):e215-e217.

doi: 10.1111/jdv.18487. Epub 2022 Sep 1.

¹ Department of Dermatology, College of Medicine, Hanyang University, Seoul, South Korea.
² Sung Kyung Jeh Skin Clinic, Seoul, South Korea.
³ Department of Pathology, College of Medicine, Hanyang University, Seoul, South Korea.

No abstract available

References

1. Jiang X, Wang H, Lee M, Lin Z. Epidermolysis bullosa pruriginosa treated with baricitinib. JAMA Dermatol. 2021;157(10):1243-4.
1. Papanikolaou M, Onoufriadis A, Mellerio J, Nattkemper L, Yosipovitch G, Steinhoff M, et al. Prevalence, pathophysiology and management of itch in epidermolysis bullosa. Br J Dermatol. 2021;184(5):816-25.
1. Kim WB, Alavi A, Walsh S, Kim S, Pope E. Epidermolysis bullosa pruriginosa: a systematic review exploring genotype-phenotype correlation. Am J Clin Dermatol. 2015;16(2):81-7.
1. Darbord D, Hickman G, Pironon N, Barbieux C, Bonnet-des-Claustres M, Titeux M, et al. Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed Th2 immunity. J Eur Acad Dermatol Venereol. 2022;36(1):133-43.
1. Clawson RC, Duran SF, Pariser RJ. Epidermolysis bullosa pruriginosa responding to dupilumab. JAAD Case Rep. 2021;16:69-71.